Literature DB >> 8770299

Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia.

K G Billingsley1, D L Fraker, G Strassmann, C Loeser, H M Fliot, H R Alexander.   

Abstract

BACKGROUND: The cellular basis for augmented cytokine production in the tumor-bearing host is not known. Recently leukemia inhibitory factor (LIF) and interleukin (IL)-6, produced by a variety of tumors, have been implicated as mediators of cachexia.
METHODS: Five murine tumor cell lines were tested for the production of these cytokines. 4JK tumor was further tested to determine if IL-1, tumor necrosis factor (TNF), or cocultivation with RAW 264 cells augmented IL-6 or LIF production.
RESULTS: 4JK from in vivo tumors produced significantly more IL-6 than did 4JK from culture, indicating that tumor production of IL-6 and LIF is potentially augmented by infiltrating macrophages. When 4JK was cocultured with RAW 264 cells, TNF, or IL-1 in vitro, a three- to 15-fold increase in tumor production of LIF and IL-6 was noted (p2 < or = 0.03). Conversely, in coculture experiments performed with a neutralizing TNF antibody, a 50% reduction in tumor production of LIF ad IL-6 was noted (p2 < 0.04). Resting RAW cells produced only minimal quantities of TNF; however, when RAW cells were exposed to tumor-conditioned supernatant from 4JK, their TNF production was markedly increased.
CONCLUSIONS: In the tumor microenvironment, host macrophages may be activated and produce inflammatory cytokines such as TNF. Local TNF then appears to act on tumor cells to stimulate production of IL-6 and LIF. Enhanced tumor production of cytokine mediators may contribute to deleterious effects of neoplastic growth on the host.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770299     DOI: 10.1007/bf02409048

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Induction of interferon-beta 2/interleukin-6 (IL-6) by cytokine administration and detection of circulating interleukin-6 in the tumor-bearing state.

Authors:  D M Jablons; J K McIntosh; J J Mulé; R P Nordan; S Rudikoff; M T Lotze
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

2.  Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models.

Authors:  B A Sherry; J Gelin; Y Fong; M Marano; H Wei; A Cerami; S F Lowry; K G Lundholm; L L Moldawer
Journal:  FASEB J       Date:  1989-06       Impact factor: 5.191

3.  Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor.

Authors:  G Strassmann; Y Masui; R Chizzonite; M Fong
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

4.  Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat.

Authors:  M C Stovroff; D L Fraker; J A Swedenborg; J A Norton
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

5.  Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids.

Authors:  P Waring; K Wycherley; D Cary; N Nicola; D Metcalf
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia.

Authors:  H N Langstein; G M Doherty; D L Fraker; C M Buresh; J A Norton
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

7.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

Review 8.  Cytokines and their role in the pathophysiology of cancer cachexia.

Authors:  M J McNamara; H R Alexander; J A Norton
Journal:  JPEN J Parenter Enteral Nutr       Date:  1992 Nov-Dec       Impact factor: 4.016

9.  Evidence for tumour necrosis factor/cachectin production in cancer.

Authors:  F Balkwill; R Osborne; F Burke; S Naylor; D Talbot; H Durbin; J Tavernier; W Fiers
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

10.  Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.

Authors:  D L Fraker; H N Langstein; J A Norton
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  7 in total

Review 1.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  The Molecular Basis and Therapeutic Potential of Leukemia Inhibitory Factor in Cancer Cachexia.

Authors:  Ruijiang Zeng; Chang Tong; Xiangyang Xiong
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

Review 3.  Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem.

Authors:  Robert D Winfield; Matthew J Delano; Kalyan Pande; Philip O Scumpia; Drake Laface; Lyle L Moldawer
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008 Nov-Dec       Impact factor: 4.016

4.  Comparative analysis of macrophage associated vectors for use in genetic vaccine.

Authors:  Mohammad Feraz Ahsan; Milind M Gore
Journal:  Genet Vaccines Ther       Date:  2011-06-18

5.  Hochuekkito (TJ-41), a Kampo Formula, Ameliorates Cachexia Induced by Colon 26 Adenocarcinoma in Mice.

Authors:  Suzu Yae; Fumiyuki Takahashi; Toshifumi Yae; Takuji Yamaguchi; Rika Tsukada; Kengo Koike; Kunihiko Minakata; Akiko Murakami; Fariz Nurwidya; Motoyasu Kato; Mayumi Tamada; Momoko Yoshikawa; Hiroyuki Kobayashi; Kuniaki Seyama; Kazuhisa Takahashi
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-24       Impact factor: 2.629

6.  Systemic Inflammation in Cachexia - Is Tumor Cytokine Expression Profile the Culprit?

Authors:  Emidio M de Matos-Neto; Joanna D C C Lima; Welbert O de Pereira; Raquel G Figuerêdo; Daniela M Dos R Riccardi; Katrin Radloff; Rodrigo X das Neves; Rodolfo G Camargo; Linda F Maximiano; Flávio Tokeshi; José P Otoch; Romina Goldszmid; Niels O S Câmara; Giorgio Trinchieri; Paulo S M de Alcântara; Marília Seelaender
Journal:  Front Immunol       Date:  2015-12-24       Impact factor: 7.561

7.  Macrophage Depletion in Elderly Mice Improves Response to Tumor Immunotherapy, Increases Anti-tumor T Cell Activity and Reduces Treatment-Induced Cachexia.

Authors:  Lelinh Duong; Hannah G Radley-Crabb; Joanne K Gardner; Federica Tomay; Danielle E Dye; Miranda D Grounds; Fiona J Pixley; Delia J Nelson; Connie Jackaman
Journal:  Front Genet       Date:  2018-11-06       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.